Latest research on Harvoni

Sofosbuvir is a medication used as part of combination therapy to treat hepatitis C virus (HCV) infection or HCV and HIV co-infection. Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B polymerase. Sofosbuvir was approved by the FDA in December 2013, and is marketed under the brand name Sovaldi.

Harvoni side effects

In particular, treatments Harvoni and Viekira Pak both achieve higher QALYs with reduced costs, which makes the benchmark treatment no longer efficient, whereas treatments olysio + sovaldi and sofosbuvir + peginterferon + ribavirin both achieve higher QALYs but with increased costs compared to benchmark treatment. [source, 2015]
After intracellular phosphorylation, NIs like mericitabine (R7128) or sofosbuvir (GS-7977) get incorporated into the growing RNA chain as false substrates, which causes direct chain termination. [source, 2014]
The US FDA has recently (6 December, 2013) approved sofosbuvir under the brand name Sovaldi for the treatment chronic HCV infection under a breakthrough therapy designation, because it has shown a substantial improvement over the other available therapies. [source, 2014]